Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

Audio By Carbonatix

SAN FRANCISCO--(BUSINESS WIRE)--Nov 7, 2025--

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London, United Kingdom.

A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.

About Vir Biotechnology

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251107857542/en/

CONTACT: Media Contact

[email protected] Contact

[email protected]

KEYWORD: CALIFORNIA EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY INFECTIOUS DISEASES HEALTH PHARMACEUTICAL ONCOLOGY

SOURCE: Vir Biotechnology, Inc.

Copyright Business Wire 2025.

PUB: 11/07/2025 09:00 AM/DISC: 11/07/2025 09:01 AM

http://www.businesswire.com/news/home/20251107857542/en